Login
Home
Charts
Search
Watchlist
Products

Nutricircle Ltd

NUTRICIRCLE·BSE
270.000.00%Mon, 7 Sept '26

Nutricircle Ltd

NUTRICIRCLE
BSE
270.00
0.00%
|Mon, 7 Sept '26
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
300Cr
Close
Close Price
270.00
Industry
Industry
Food - Processing - Others
PE
Price To Earnings
931.03
PS
Price To Sales
14.23
Revenue
Revenue
21Cr
Rev Gr TTM
Revenue Growth TTM
329.80%
PAT Gr TTM
PAT Growth TTM
-43.40%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
120001125656
Growth YoY
Revenue Growth YoY%
44.0351.1-100.0-100.0-31.1279.4289.6151.1
Expenses
ExpensesCr
121002025555
Operating Profit
Operating ProfitCr
00-1000100000
OPM
OPM%
-12.5-13.2-7.562.41.41.23.30.40.7
Other Income
Other IncomeCr
000000000000
Interest Expense
Interest ExpenseCr
000000000000
Depreciation
DepreciationCr
000000000000
PBT
PBTCr
00-1000100000
Tax
TaxCr
000000000000
PAT
PATCr
00-1000100000
Growth YoY
PAT Growth YoY%
-300.0-1,033.3-48.62.6-112.560.7250.0108.1135.3263.6-97.433.3
NPM
NPM%
-11.1-13.2-7.562.41.41.23.30.40.7
EPS
EPS
-2.8-10.3-19.2-14.0-6.4-0.10.80.00.10.20.00.0
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
120001125656
Growth YoY
Revenue Growth YoY%
44.0351.1-100.0-100.0-31.1279.4289.6151.1
Expenses
ExpensesCr
121002025555
Operating Profit
Operating ProfitCr
00-1000100000
OPM
OPM%
-12.5-13.2-7.562.41.41.23.30.40.7
Other Income
Other IncomeCr
000000000000
Interest Expense
Interest ExpenseCr
000000000000
Depreciation
DepreciationCr
000000000000
PBT
PBTCr
00-1000100000
Tax
TaxCr
000000000000
PAT
PATCr
00-1000100000
Growth YoY
PAT Growth YoY%
-300.0-1,033.3-48.62.6-112.560.7250.0108.1135.3263.6-97.433.3
NPM
NPM%
-11.1-13.2-7.562.41.41.23.30.40.7
EPS
EPS
-2.8-10.3-19.2-14.0-6.4-0.10.80.00.10.20.00.0

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
01000002331821
Growth
Revenue Growth%
112.1-100.0-100.0680.845.3-4.6556.3329.8
Expenses
ExpensesCr
10010012431721
Operating Profit
Operating ProfitCr
-100-10000-1000
OPM
OPM%
-380.63.6-110.5-124.1-20.1-44.64.31.61.4
Other Income
Other IncomeCr
000000000000
Interest Expense
Interest ExpenseCr
000000000000
Depreciation
DepreciationCr
000000000000
PBT
PBTCr
-100-10000-1000
Tax
TaxCr
000000000000
PAT
PATCr
-100-10000-1000
Growth
PAT Growth%
-223.4102.6-974.9-426.576.8-48.317.1-15.8-263.3109.7147.6-43.4
NPM
NPM%
-373.94.5-110.8-119.1-17.7-44.14.51.71.4
EPS
EPS
-32.80.8-7.3-7.3-8.9-13.2-10.6-10.9-46.10.40.30.3
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
01000002331821
Growth
Revenue Growth%
112.1-100.0-100.0680.845.3-4.6556.3329.8
Expenses
ExpensesCr
10010012431721
Operating Profit
Operating ProfitCr
-100-10000-1000
OPM
OPM%
-380.63.6-110.5-124.1-20.1-44.64.31.61.4
Other Income
Other IncomeCr
000000000000
Interest Expense
Interest ExpenseCr
000000000000
Depreciation
DepreciationCr
000000000000
PBT
PBTCr
-100-10000-1000
Tax
TaxCr
000000000000
PAT
PATCr
-100-10000-1000
Growth
PAT Growth%
-223.4102.6-974.9-426.576.8-48.317.1-15.8-263.3109.7147.6-43.4
NPM
NPM%
-373.94.5-110.8-119.1-17.7-44.14.51.71.4
EPS
EPS
-32.80.8-7.3-7.3-8.9-13.2-10.6-10.9-46.10.40.30.3

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
0000000001011
Reserves
ReservesCr
-1-1-1-2-2-3-3-3-5-4-4
Current Liabilities
Current LiabilitiesCr
00000001000
Non Current Liabilities
Non Current LiabilitiesCr
21223334511
Total Liabilities
Total LiabilitiesCr
11211112178
Current Assets
Current AssetsCr
11211112178
Non Current Assets
Non Current AssetsCr
10000000000
Total Assets
Total AssetsCr
11211112178
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
0000000001011
Reserves
ReservesCr
-1-1-1-2-2-3-3-3-5-4-4
Current Liabilities
Current LiabilitiesCr
00000001000
Non Current Liabilities
Non Current LiabilitiesCr
21223334511
Total Liabilities
Total LiabilitiesCr
11211112178
Current Assets
Current AssetsCr
11211112178
Non Current Assets
Non Current AssetsCr
10000000000
Total Assets
Total AssetsCr
11211112178

Cash Flow

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
00-10000-1-2-4-2
Investing Cash Flow
Investing Cash FlowCr
-11000000000
Financing Cash Flow
Financing Cash FlowCr
10100001251
Net Cash Flow
Net Cash FlowCr
0000000001-1
Free Cash Flow
Free Cash FlowCr
00-10000-1-2-4-3
CFO To PAT
CFO To PAT%
48.0-828.6375.929.7105.262.8117.2217.7124.4-3,285.3-813.9
CFO To EBITDA
CFO To EBITDA%
47.1-1,043.0377.024.1105.547.6112.5191.6123.2-3,400.6-836.9
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
00-10000-1-2-4-2
Investing Cash Flow
Investing Cash FlowCr
-11000000000
Financing Cash Flow
Financing Cash FlowCr
10100001251
Net Cash Flow
Net Cash FlowCr
0000000001-1
Free Cash Flow
Free Cash FlowCr
00-10000-1-2-4-3
CFO To PAT
CFO To PAT%
48.0-828.6375.929.7105.262.8117.2217.7124.4-3,285.3-813.9
CFO To EBITDA
CFO To EBITDA%
47.1-1,043.0377.024.1105.547.6112.5191.6123.2-3,400.6-836.9

Ratios

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
4111156198409300
Price To Earnings
Price To Earnings
46.11,649.61,365.0931.0
Price To Sales
Price To Sales
15.72.13.52.42.373.323.114.2
Price To Book
Price To Book
-0.3-1.8-0.8-0.5-0.3-1.5-1.535.959.143.3
EV To EBITDA
EV To EBITDA
-5.9132.9-3.0-8.3-12.9-21.7-9.41,689.81,408.61,002.6
Profitability Ratios
Profitability Ratios
GPM
GPM%
7.750.34.2-11.111.51.140.08.68.6
OPM
OPM%
-380.63.6-110.5-124.1-20.1-44.64.31.61.4
NPM
NPM%
-373.94.5-110.8-119.1-17.7-44.14.51.71.4
ROCE
ROCE%
-80.72.9-14.9-176.9-39.9-100.0-68.9-40.8-110.21.93.83.8
ROE
ROE%
143.1-3.825.157.011.714.810.911.228.92.24.34.3
ROA
ROA%
-72.11.9-11.7-144.5-25.6-50.8-34.9-21.6-85.11.83.63.6
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
4111156198409300
Price To Earnings
Price To Earnings
46.11,649.61,365.0931.0
Price To Sales
Price To Sales
15.72.13.52.42.373.323.114.2
Price To Book
Price To Book
-0.3-1.8-0.8-0.5-0.3-1.5-1.535.959.143.3
EV To EBITDA
EV To EBITDA
-5.9132.9-3.0-8.3-12.9-21.7-9.41,689.81,408.61,002.6
Profitability Ratios
Profitability Ratios
GPM
GPM%
7.750.34.2-11.111.51.140.08.68.6
OPM
OPM%
-380.63.6-110.5-124.1-20.1-44.64.31.61.4
NPM
NPM%
-373.94.5-110.8-119.1-17.7-44.14.51.71.4
ROCE
ROCE%
-80.72.9-14.9-176.9-39.9-100.0-68.9-40.8-110.21.93.83.8
ROE
ROE%
143.1-3.825.157.011.714.810.911.228.92.24.34.3
ROA
ROA%
-72.11.9-11.7-144.5-25.6-50.8-34.9-21.6-85.11.83.63.6
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
A company that began as a textile trader in 1993 and is now a BSE-listed micro-cap stitching together India’s premier agricultural research institutions to build a pipeline from farm to functional ingredient - that is Nutricircle Ltd. It transformed into a pure-play nutraceutical business under the leadership of Managing Director Hitesh Mohanlal Patel, who took control in 2013 and later consolidated his holding to over 62% while converting personal loans into equity to recapitalise the company. The recurring approach is to secure a long-term, sustainable supply of native crops - quinoa, millets, chickpea - through contract farming and institutional tie-ups, then apply R&D to isolate plant proteins and develop nutrition products, a philosophy articulated consistently across every annual report. # Business segments A single engine - plant protein ingredients and nutrition products derived from indigenous grains, built on a foundation of research partnerships and contract farming, now reaching for international markets through a distribution agreement and a newly incorporated European subsidiary. ## 1. Plant protein and nutrition products: from Indian farms to functional ingredients **The company isolates protein from quinoa, millets, chickpea and other native crops using research partnerships with India’s top agricultural institutes, then sells the resulting concentrates and flours as ingredients to food, beverage and nutrition companies - with a newly signed exclusive distributor now handling all sales.** - **Research partnerships are the R&D backbone** - the company has tied up with NAARM for a quinoa incubation and demonstration centre on 1.8 acres, with NAARM for nutritional flour and noodle technology, with the Indian Institute of Millet Research for plant protein from jowar, ragi and bajra, and with ICRISAT for high-protein chickpea cultivars, so it accesses institutional science rather than building a large in-house lab. - **Farmers grow the raw material on contract** - quinoa cultivation has been taken up on about 30 acres through a tie-up with farmers at Nagar Karnool, giving the company a dedicated supply chain without owning farmland, though crops have been vulnerable to adverse climate. - **The product range now spans 28% to 95% protein content** - launched as the “Next Generation of Plant-Based Proteins” at Gulfood Dubai 2026, the line includes protein concentrates and isolates from foxtail millet, amaranth, pearl millet, horse gram, lentils and high-protein chickpea, targeting food and beverage, nutraceutical, sports nutrition, pharmaceutical, bakery and snack manufacturers. - **One exclusive distributor handles the entire sales pipeline** - a five-year agreement signed in August 2025 with Barentz Distribution India gives Barentz exclusive rights to market, distribute and resell Nutricircle’s products in the territory, with all customer enquiries routed to Barentz and purchase orders accepted up to 115% of the estimated annual volume. - **A European subsidiary opens the door to international markets** - Nutricircle Europe ApS was incorporated in Denmark in May 2026, wholly owned, to develop, produce and trade plant-based ingredients and food products, though it had not yet commenced operations at incorporation. # Group structure and partners **A tightly held promoter-led company with no operating subsidiaries as of the last balance-sheet date, but with a web of institutional research partnerships that function as its de facto innovation engine.** - **The board is five-strong with three independents** - the Executive Managing Director is joined by a Whole Time Director and three Independent Directors, while the statutory audit is handled by NSVR & Associates LLP and secretarial audit by M/s Jain Mayuri & Associates. - **Research muscle comes from outside the company** - partnerships span NAARM, PJTSAU, the Indian Institute of Millet Research (an ICAR body), ICRISAT, and AgHub (the agri-innovation hub of PJTSAU), with AgHub holding board observer and inspection rights but no claim over Nutricircle’s intellectual property. - **A state-government MOU signals geographic expansion** - an agreement with the Government of Assam proposes up to Rs. 100 crores of investment in a food-processing and black-rice protein isolation project, valid for 12 months from February 2025. - **An acquisition is in principle on the cards** - the company decided to acquire Himalaya Nutravedics India Private Limited as a going concern, with final cost and payment mode to be settled.

Documents — Nutricircle Ltd

  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/hylwpcfj00egdpv1782pbc1l.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/emfmg7zvveyv3ysheimjs06i.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/rlz5jyktp8ikaxhj29ddi8gg.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/3c7l8zu2gym66suv25clz5ah.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/qvq7n93vw28ixescyzw47h2l.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/uohp8tev5tzckt38nu99cz3k.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/y95tvl9frro39yd94cyvd0uf.pdf
  • Q1 FY2025 Quarterly Result (Jun 2024, PDF): https://www.stockscans.in/document/fafka4sw1kh4hx3n76hwdj7t.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/5l9tsvk29vxs6wef70agfuxr.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/ukcindjsu9smrjkelod4u3md.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/dzfcyd1481nqcx1xahwenz1r.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/vk70h02zlas88e49pv969n9x.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/7qeg7c88qayputzz6d6s4r8f.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/c01qdig8f08b2m5m6jwey2uo.pdf